Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ-006
- Development stage
- Preclinical
- Lead developer
- Jing Medicine Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HJ-006 is an orally active, brain-penetrant, small molecule non-hallucinogenic neuroplastogen (synaptogenic agent) being developed by Jing Medicine Technology for the treatment of central nervous system disorders, including major depressive disorder (MDD). It is designed to promote neuroplasticity, neurite outgrowth, and synaptogenesis without the hallucinogenic effects or 5-HT2B-mediated cardiotoxicity typically associated with serotonergic psychedelics. In preclinical models, HJ-006 demonstrated rapid and sustained antidepressant-like efficacy, rescued corticosterone-impaired hippocampal activity, and exhibited 5-HT2B antagonist activity.
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on HJ-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ-006.